Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]
28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meetingOverall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reachedResults from Cohorts A and B of the CARTITUDE-2 study […]
SOMERSET, N.J.—(BUSINESS WIRE)—June 3, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase 1 clinical trial in the United […]
SOMERSET, N.J. — (BUSINESS WIRE) —June 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results. “The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for […]
SOMERSET, N.J.— (BUSINESS WIRE)—August 4, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II director […]
SOMERSET, NJ – July 25, 2022 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it intends to offer and sell $250 million of American Depositary Shares (“ADSs”), each representing two ordinary shares, in an underwritten public offering. All […]
SOMERSET, N.J.— (BUSINESS WIRE) —April 21, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the achievement of a $50 million milestone under its collaboration agreement with Janssen Biotech, Inc. (Janssen) for ciltacabtagene autoleucel (cilta-cel), now marketed in the United […]
SOMERSET, N.J.— (BUSINESS WIRE) —April 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Guowei Fang, Ph.D., as Senior Vice President, Global Head of Research and Early Development. Dr. Guowei Fang is an accomplished scientist and […]
Ciltacabtagene autoleucel, if approved by the European Commission (EC), will be Legend Biotech’s first EC-approved product SOMERSET, N.J.— (BUSINESS WIRE) —March 25, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the Committee for Medicinal Products for Human Use […]
SOMERSET, N.J. — March 23, 2022 — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, was named Newcomer of the Year at the tenth annual Foreign Investment Trophy ceremony hosted by Flanders Investment & Trade (FIT). Flanders Investment and Trade is a […]
